CLINICAL_TRIALS
trial_result
· 2016-05-16
Clinical Trial Update: BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME). [Phase 3]
Summary
This clinical trial update reports results from EMPA-REG OUTCOME, a phase 3 cardiovascular outcomes study of empagliflozin (BI 10773) in adults with type 2 diab…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2016-05-16